A novel aberrant splice site mutation in the *APC* gene

G S Charames, H Cheng, C A Gilpin, A G W Hunter, T Berk, B Bapat

J Med Genet 2002;**39**:754–757

Familial adenomatous polyposis (FAP) is an inherited, autosomal dominant syndrome characterised by the presence of multiple (>100) adenomatous polyps in the colon and rectum. These polyps, if left untreated, progress to colorectal cancer (CRC), typically by the age of 40 years.¹ Other clinical features include variable age of onset of polyposis (age 10–40 years) and variable expression.² FAP accounts for about 1% of all colorectal cancers.^{3,4} In addition to colonic polyps, FAP patients may present premalignant lesions in the upper gastrointestinal tract, extraintestinal manifestations such as osteomas and epidermoid cysts, desmoid formation, congenital hypertrophy of the retinal pigment epithelium (CHRPE), and other malignant changes, such as small bowel cancer and tumours of the brain and thyroid gland.²

FAP is caused by the dominant inheritance of germline mutations of the adenomatous polyposis coli (*APC*, MIM 175100) tumour suppressor gene.^{3–6} *APC* is a 312 kDa protein translated from a major transcript consisting of 15 exons with the last exon occupying 77% of the total protein. Additional *APC* transcripts occur because of alternative splicing of exons 3–4, 9, 10A/X, and 14.^{7–9} The majority of *APC* mutations result in the formation of a truncated protein¹⁰ and most germline mutations are reported in the first half of the gene.^{11–13} Mutant *APC* proteins lack the potentially important functional motifs including binding domains for β -catenin, microtubulin, and EB1.^{14–16} Furthermore, the armadillo repeats are located between *APC* exons 10–14, and deletion of this domain disrupts interactions between *APC* and other partner proteins including PP2A and ASEF.^{17,18}

The GT and AG sequence motifs are highly conserved consensus splice donor and acceptor site sequences at the intron-exon boundaries.^{19,20} Splice site defects account for approximately 15% of disease causing point mutations of various genes.²¹ The majority of splice site mutations consist of splice donor (SD) site defects. The splice acceptor (SA) site mutations mostly involve the invariant AG sequence and typically cause exon skipping. Only about 13% of all SA mutations result in the creation of novel splice sites.

Truncating *APC* mutations mostly include nonsense point mutations or small insertions/deletions (<http://perso.curie.fr/Thierry.Soussi/APC.html>). To date, few SA mutations have been reported for *APC*. Published reports have either shown SA mutations resulting in exonic deletions²² or have not characterised SA substitutions further, simply citing them as “splice acceptor defect”.²³ Here we describe a family with a classical polyposis phenotype that harbours a germline SA mutation in the invariant AG sequence of *APC* exon 8, generating a novel cryptic splice acceptor site immediately downstream. This splicing defect results in a single base pair deletion at the beginning of the exon at the transcriptional level and leads to a premature truncation within *APC* exon 8.

PATIENTS AND METHODS

Selection of patients

This kindred was referred to the molecular diagnostic laboratory at the Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, as part of a provincial predictive genetic

screening programme for FAP. Affected subjects had the classical polyposis phenotype, characterised by numerous adenomatous polyps. Endoscopic, operative, and histopathological data were collected retrospectively on all affected patients and complete follow up information was obtained as well. Predictive genetic testing was offered to clinically affected and at risk subjects, with pre- and post-test genetic counselling as described previously.²⁴ Patient accrual, sample collection, and genetic screening were performed according to guidelines of the Ethics Committee of the University of Toronto.

Molecular genetic analysis

The protein truncation test (PTT) assay was initially used to screen for underlying germline *APC* mutations in this kindred.²⁵ Blood samples were obtained from patients and lymphocytes were isolated using NH_4Cl -Tris (1.4 mol/l NH_4Cl , 17 mmol/l Tris, pH 7.6). Samples were mixed by inversion, incubated at 37°C for 25 minutes, and spun at 1600 rpm for 10 minutes. The WBC pellet on ice was resuspended in PBS and spun at 1600 rpm for 10 minutes. RNA extraction was performed using TRIzol according to the manufacturer's protocol (Invitrogen Life Technologies, Burlington, Canada), and DNA extraction was performed using a saturated salt solution.²⁶ Reverse transcription PCR was performed by use of standard techniques. In brief, cDNA was generated from total RNA (5 μg) by use of random hexamers $\text{pd}(\text{N}_6)$ (Amersham Pharmacia, Piscataway, NJ), oligodT (Invitrogen Life Technologies), 1 $\times$ first strand buffer, 0.5 mmol/l of deoxynucleotide triphosphate, 5 mmol/l DTT, and 200 units of SuperScript II (Invitrogen Life Technologies). cDNA was synthesised by incubating at 45°C for one hour followed by 70°C for 15 minutes.

APC exon 15 was amplified in four overlapping segments, as described previously.²⁵ Exons 1–14 were amplified in two overlapping segments: 1A (exons 1–9) and 1B (exons 8–14). The 5' end of each forward primer had a T7 promoter sequence and a translation initiation site (5' GGA TCC TAA TAC GAC TCA CTA TAG GGA GAC CAC C 3') for coupled in vitro transcription and translation. Amplification of the region (segment 1A) that harboured the *APC* mutation in this kindred was performed using primers SIIF (5' ATG GCT GCA GCT TCA TAT GAT C 3', *APC* nucleotides 1–22) and 9AR (5' AGC CTC TTT ACT GCC CCG 3', *APC* nucleotides 1120–1137). PCR conditions were as follows: initial denaturation at 95°C for two minutes; 35–40 cycles, each consisting of denaturation at 95°C for 30 seconds, annealing at 63°C for one minute 30 seconds, and extension at 70°C for two minutes; and a final extension at 70°C for five minutes. Five μl aliquots of PCR products were electrophoresed on a 1.5% agarose gel, in order to confirm amplification.

Abbreviations: FAP, familial adenomatous polyposis; CRC, colorectal cancer, CHRPE, congenital hypertrophy of the retinal pigment epithelium; APC, adenomatous polyposis coli; SD, splice donor; SA, splice acceptor; PTT, protein truncation test; AAPC, attenuated APC

Figure 1 (A) Pedigree of the FAP family with a classical polyposis phenotype described in this study. Affected and unaffected members are shown as solid and open symbols, respectively. (B) PTT analysis shows APC protein truncation (33 kDa) for all affected members (patients I.1, II.1, II.3, II.5). (C) RT-PCR and sequence analysis with reverse primer (AP8R) shows a "G" deletion in all affected members. (D) Automated sequencing of genomic DNA shows G>A substitution in an affected member (bottom panel) compared to the wild type sequence (top panel).

The *in vitro* synthesised PTT assay was performed by use of a commercial kit (TNT T7 Quick Coupled Transcription/Translation System; Promega, Madison, WI), according to the manufacturer's protocol. In brief, TNT Quick Master Mix (Promega) and ^{35}S -methionine (Amersham Pharmacia) were added to the RT-PCR product and incubated at 30°C for 90 minutes. SDS loading buffer/B-mercaptoethanol (19:1) was added to the sample before a flash spin at maximum speed (14 000 rpm for two minutes). Protein products were electrophoresed on a 4-15% Linear Gradient Tris-HCl gel (Bio-Rad Laboratories, Hercules, CA). Positive PTT results were confirmed by two independent PCR reactions.

For sequence determination, RT-PCR products of the putative PTT positive samples were electrophoresed on a 1.5% agarose gel for 45-60 minutes at 100 V and were stained with ethidium bromide. The band of interest was excised with a sterile scalpel blade, and DNA was extracted by use of the QIAquick Gel Extraction Kit (QIAGEN Inc, Mississauga, Canada). The dideoxy mediated chain termination method was used for DNA sequencing.²⁷ For this purpose, we used $\alpha[^{32}\text{P}]$ dideoxynucleotide and a ThermoSequenase radiolabelled terminator sequencing kit (Amersham Pharmacia) with primers AP7F (5' CAT GGC AAC TTC TGG TAA TG 3', APC nucleotides 810-829), AP8R (5' CAC TGG CTG TTT CAT GGT C 3', APC nucleotides 853-871), and 9AR. Sequencing was performed according to the manufacturer's protocol. Finally, the gel was autoradiographed by use of BioMax MR film (Eastman Kodak Company, Toronto, Canada) for 24-48 hours at room temperature.

In order to confirm the mutation identified at the transcriptional level, genomic DNA sequencing was performed using intronic primers 8FN (5' TAA ATT ATA CCA TCT ATA ATG TGC 3', APC EX8-12 to EX8-35) and 8RN (5' GCA TTA GTG ACC AGG GTT TG 3', APC EX8+15 to EX8+34), flanking APC exon 8. Dideoxy sequencing of the PCR products was performed using a BIGDYE dideoxy sequencing ready reaction kit and analysed on an ABI 310 automated sequencer (PE Foster City, California, USA).

RESULTS AND DISCUSSION

This is the first report of a complex germline APC mutation caused by recruitment of a novel cryptic SA site resulting in familial polyposis. In this family, PTT analysis initially showed a truncated mutant APC protein in the germline of affected FAP patients (fig 1). RT-PCR and sequence analysis identified a "G" deletion at the beginning of APC exon 8 (nucleotide 834), resulting in a stop (TGA) in the same exon (codon 293). Further sequencing of genomic DNA, however, did not show the same "G" deletion as expected, but showed a G>A substitution mutation at -1 SA site of APC exon 8. This substitution results in the use of a cryptic splice acceptor site immediately adjacent to the mutation, which creates an apparent "G" deletion at the transcriptional level (fig 2). This germline mutation was identified in all clinically affected members of the family.

SA substitution mutations are usually predicted to result in an exonic deletion and therefore further investigations of the mRNA transcripts are not always carried out.²³ Genotype-phenotype correlative studies in FAP have shown that

Figure 2 Illustration representing a cryptic splice site generated from a point mutation in the invariant "G" at the -1 position of the authentic splice acceptor site sequence of APC exon 8 (A). The cryptic splice site causes a single base frameshift resulting in altered amino acid sequence and a stop codon within the same exon (B).

germline mutations at the extreme 3' end of the APC gene that retain different functional domains lead to a milder form of FAP, also known as attenuated adenomatous polyposis coli (AAPC).²⁵ If SA substitution in this family were to cause exon skipping, then it would have resulted in an in frame deletion of APC exon 8. Such a mutant APC transcript would have maintained all the functional domains present in the wild type APC and would be predicted to result in AAPC. All affected patients from this family have presented with the classical polyposis phenotype, supporting the use of newly created cryptic splice acceptor site resulting in APC truncation within exon 8. Indeed, truncating mutations in APC exon 8 have been associated with the classical FAP phenotype.²⁸

A survey of mutation databases for other cancer predisposing genes (*BRCA1*, *BRCA2*, *p53*, *MLH1*, and *MSH2*)* as well as APC, indicates that splice site mutations account for ~5-12% of all mutations reported (excluding unclassified variants). Among these, very few splice acceptor (-1) G>A alterations have been reported. To our knowledge, the use of a cryptic splice site similar to the one observed in this family has never been reported for any of these genes.

It is challenging to derive an explanation for the preference of cryptic SA site over exon skipping in this family. Splice acceptor sites are much less conserved than splice donor sites. An invariant AG sequence, a pyrimidine rich track of 10-20 nucleotides upstream of this sequence,²⁹ and a conserved sequence element known as "the branchpoint", 18-40 bp upstream of the 3' splice site,³⁰ are among the recognition elements required by the spliceosome assembly for efficient splicing of exons. Using these three recognition elements, Shapiro and Senapathy³¹ devised a method of ranking and scoring potential splice sites by comparing the observed splice site sequences of many genes to the consensus splice junction sequences. They suggested that a higher score correlated with a greater probability for the usage of the splice site under investigation. When we calculated the score for the APC IVS7-1G>A alteration, as expected, the score for the mutant SA site was lower than the score for the wild type splice acceptor site (67 versus 83). However, the score for the proposed cryptic splice site immediately downstream was higher than the mutant splice site (81 versus 67). Interestingly, despite a higher score of 90, the exon 9 SA site was not used to generate mutant APC transcript in this family. One possible reason for this apparent discrepancy may be the greater distance that spliceosome assembly would have to cover, relative to the cryptic splice acceptor site.

In summary, we identified a germline APC mutation in the conserved splice acceptor sequence that has activated a cryptic splice site over the often preferred deletion of the exon. Whether a similar mechanism underlies mutations in other genes remains to be investigated.

Electronic database information. *Mutation databases: APC: <http://perso.curie.fr/Thierry.Soussi/APC.html>. *BRCA1* and *BRCA2*: http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/. *MLH1* and *MSH2*: <http://www.nfdht.nl/>. *P53*: <http://www.iarc.fr/p53/index.html>.

Authors' affiliations

G S Charames, H Cheng, B Bapat, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
G S Charames, B Bapat, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada
T Berk, B Bapat, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Canada
G S Charames, B Bapat, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
C A Gilpin, A G W Hunter, Eastern Ontario Regional Genetics Program, Children's Hospital of Eastern Ontario, Ottawa, Canada

Correspondence to: Dr B Bapat, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Room 992B, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5; bapat@msri.on.ca

REFERENCES

- Gardner EJ**. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. *Am J Hum Genet* 1951;**3**:167-76.
- Giardiello FM**, Krush AJ, Petersen GM, Booker SV, Kerr M, Tong LL, Hamilton SR. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. *Gastroenterology* 1994;**106**:1542-7.
- Groden J**, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991;**66**:589-600.
- Kinzler KW**, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, Finnear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I, Nakamura Y. Identification of FAP locus genes from chromosome 5q21. *Science* 1991;**253**:661-5.
- Joslyn G**, Carlson M, Thliveris A, Albertsen H, Gelbert L, Samowitz W, Groden J, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R. Identification of deletion mutations and three new genes at the familial polyposis locus. *Cell* 1991;**66**:601-13.
- Nishisho I**, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P, Markham A, Krush AJ, Petersen G, Hamilton SR, Nilbert MC, Levy DB, Bryan TM, Preisinger AC, Smith KJ, Su L-K, Kinzler KW, Vogelstein B. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 1991;**253**:665-9.
- Samowitz WS**, Thliveris A, Spirio LN, White R. Alternatively spliced adenomatous polyposis coli (APC) gene transcripts that delete exons mutated in attenuated APC. *Cancer Res* 1995;**55**:3732-4.
- Xia L**, St Denis KA, Bapat B. Evidence for a novel exon in the coding region of the adenomatous polyposis coli (APC) gene. *Genomics* 1995;**28**:589-91.
- Bala S**, Kraus C, Wijnen J, Meera Khan P, Ballhausen WG. Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. *Hum Genet* 1996;**98**:528-33.

- 10 **Wallis YL**, Morton DG, McKeown CM, Macdonald F. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. *J Med Genet* 1999;**36**:14-20.
- 11 **Nagase H**, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. *Hum Mutat* 1993;**2**:425-34.
- 12 **Beroud C**, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res* 1996;**24**:121-4.
- 13 **De Vries EM**, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS, Sommer SS. Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. *Hum Mutat* 1996;**7**:202-13.
- 14 **Smith KJ**, Johnson KA, Bryan TM, Hill DE, Markowitz S, Willson JK, Parakeva C, Petersen GM, Hamilton SR, Vogelstein B, Kinzler KW. The APC gene product in normal and tumor cells. *Proc Natl Acad Sci USA* 1993;**90**:2846-50.
- 15 **Rubinfeld B**, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. *Science* 1993;**262**:1731-4.
- 16 **Su LK**, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. *Science* 1993;**262**:1734-7.
- 17 **Seeling JM**, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. *Science* 1999;**283**:2089-91.
- 18 **Kawasaki Y**, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, Higuchi O, Akiyama T. Asef, a link between the tumor suppressor APC and G-protein signaling. *Science* 2000;**289**:1194-7.
- 19 **Mount SM**. A catalogue of splice junction sequences. *Nucleic Acids Res* 1982;**10**:459-72.
- 20 **Stephens RM**, Schneider TD. Features of spliceosome evolution and function inferred from an analysis of the information at human splice sites. *J Mol Biol* 1992;**228**:1124-36.
- 21 **Krawczak M**, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. *Hum Genet* 1992;**90**:41-54.
- 22 **Spirio L**, Green J, Robertson J, Robertson M, Otterud B, Sheldon J, Howse E, Green R, Groden J, White R, Leppert M. The identical 5' splice-site acceptor mutation in five attenuated APC families from Newfoundland demonstrates a founder effect. *Hum Genet* 1999;**105**:388-98.
- 23 **van der Luijt RB**, Khan PM, Vasen HF, Tops CM, van Leeuwen-Cornelisse IS, Wijnen JT, van der Klift HM, Plug RJ, Griffioen G, Fodde R. Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and Southern analysis. *Hum Mutat* 1997;**9**:7-16.
- 24 **Soravia C**, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. *Am J Pathol* 1999;**154**:127-35.
- 25 **Soravia C**, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S, Cohen Z, Bapat B. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. *Am J Hum Genet* 1998;**62**:1290-301.
- 26 **Miller SA**, Dykes DD, Polesky HF. A simple salting out procedure for extraction DNA from human nucleated cells. *Nucleic Acids Res* 1988;**16**:1215.
- 27 **Sanger F**, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA* 1977;**74**:5463-7.
- 28 **Giardiello FM**, Brensinger JD, Luce MC, Petersen GM, Cayouette MC, Krush AJ, Bacon JA, Booker SV, Bufill JA, Hamilton SR. Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene. *Ann Intern Med* 1997;**126**:514-19.
- 29 **Chiara MD**, Gozani O, Bennett M, Champion-Arnaud P, Palandjian L, Reed R. Identification of proteins that interact with exon sequences, splice sites, and the branchpoint sequence during each stage of spliceosome assembly. *Mol Cell Biol* 1996;**16**:3317-26.
- 30 **Green MR**. Pre-mRNA splicing. *Annu Rev Genet* 1986;**20**:671-708.
- 31 **Shapiro MB**, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res* 1987;**15**:7155-74.

What's in the next issue

Future content

See which articles have just been accepted for publication and preview the table of contents for the next issue a month before it is published

www.jmedgenet.com